1 active not recruiting, 1 completed, 1 enrolling by invitation. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Enrolling by invitation 1 |
| Phase 2 | 1 | Completed 1 |
Follow Elixirgen Therapeutics, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rollover Study From EXG-US-01 EXG34217 - Telomere Biology Disorders With Bone Marrow Failure | Phase 1 | Enrolling by invitation | Elixirgen Therapeutics, Inc. | 12 | 2024-01-01 | 2024-07-12 |
| Safety and Immunogenicity of EXG-5003 EXG-5003, Placebo - COVID-19 | Phase 1 / Phase 2 | Completed | Fujita Health University | 40 | 2021-04-28 | 2023-01-26 |
| Study to Evaluate of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure EXG34217 - Telomere Shortening, Bone Marrow Failure | Phase 1 | Active not recruiting | Elixirgen Therapeutics, Inc. | 12 | 2021-04-08 | 2026-02-06 |
Bone Marrow Failure Disorders (1) · COVID-19 (1)
United States (2) · Japan (1)
Kasiani Myers, MD (2) · Yohei Doi, MD (1)